Spotlight Growth
No Result
View All Result
Sunday, May 15, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Longeveron, Inc. (NASDAQ: LGVN) Shares Skyrocket 175% After U.S. FDA Approves Lomecel-B for Rare Pediatric Disease Designation

by admin
November 18, 2021
in Bio/Med/Pharma
0
Longeveron NASDAQ LGVN FDA RPD Designation Spotlight Growth

Longeveron NASDAQ LGVN FDA RPD Designation Spotlight Growth

Longeveron, Inc. (NASDAQ: LGVN) is engaged as a clinical-stage biotechnology company, which is specifically focused on the research, development and testing of cell therapies to treat age-related and life-threatening illnesses. Shares of the biotech company are soaring 175% through early trading on Thursday, November 18, 2021. Over the past three months, Longeveron has seen average daily volume of 121,990 shares. However, volume of 170.64 million shares or dollar volume of around $1.37 billion, has already exchanged hands through early trading Thursday.

Shares of Longeveron are surging after the company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for its Lomecel-B candidate for the treatment of Hyproplastic Left Heart Syndrome (HLHS). HLHS is a rare and life-threatening congenital heart defect found in infants. Phase 2 clinical trials are underway for Lomecel-B.

Around 1,000 babies in the U.S. are born with HLHS every year. Phase 2 clinical trials are underway for Lomecel-B. HLHS leads to an underdeveloped left ventricle, which limits the heart’s ability to pump blood throughout the body. In order to treat HLHS, three surgical procedures are required over a period of five years. The procedures configure the right ventricle to pump blood throughout the body.

Longeveron’s clinical testing is evaluating the safety and efficicay of its Lomecel-B candidate, which is an injection into the right ventricle during the second surgery. The clinical trials are also testing Lomecel-B’s effect on cardiac function and other health endpoints.

Phase 1 trials have already shown strong promise. Every single infant enrolled during the Phase 1 trials were alive and did not require a transplant between 2-3.5 years post-surgery. The infants’ height, weight and growth patterns were also a match to those of healthy babies.

“We are pleased by FDA’s acknowledgment of the urgent need for a safe and effective treatment for children born with this rare and devastating congenital heart defect,” stated Longeveron co-founder and Chief Science Officer Joshua M. Hare, M.D. “We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial. Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: biopharmaceuticalsbiotechbiotechnologybiotechnology stocksclinical trialscommon stockday tradingemerging growthFDAhealthhealth stockshealthcareinvestinginvesting newsinvestmentLGVNLGVN stockLongeveronLongeveron stockmedicalmedical stocksmicrocap stocksNASDAQNASDAQ stocksnewspharmaceuticalspublic companyreddit stocksRobinhoodrobinhood armyrobinhood stocksRPD designationsalesservicessmall cap biotech stockssmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatmentWSBWSB stocks
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Nvidia Ethereum Video Card Crypto

Nvidia Announces New Chip Specifically For Ethereum Mining

0
Fandifi CSE FDM NFT Gamification Platform Spotlight Growth

Fandifi (CSE: FDM) Rewards Fan Engagement with NFT-Based Gamification Platform

May 13, 2022
York Harbour Metals TSXV YORK Copper Drilling Program Spotlight Growth

York Harbour Metals (TSXV: YORK) (OTC: YORKF) Exploration Results Position them to Meet Rising Copper Demands

May 13, 2022
Squarespace NYSE SQSP Q1 2022 Financial Results Spotlight Growth

Squarespace (NYSE: SQSP) Side-Steps Tech Rout After Reporting Strong First Quarter 2022 Financial Results, Announces $200 Million Share Buyback Program

May 12, 2022
Play the Space Race with AST SpaceMobile NASDAQ ASTS Spotlight Growth

Play the Space Race with AST SpaceMobile (NASDAQ: ASTS)

May 11, 2022

Recent News

Fandifi CSE FDM NFT Gamification Platform Spotlight Growth

Fandifi (CSE: FDM) Rewards Fan Engagement with NFT-Based Gamification Platform

May 13, 2022
York Harbour Metals TSXV YORK Copper Drilling Program Spotlight Growth

York Harbour Metals (TSXV: YORK) (OTC: YORKF) Exploration Results Position them to Meet Rising Copper Demands

May 13, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • OTC:LUSI
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested